Five severe COVID-19 pneumonia patients treated with triple combination therapy with lopinavir/ritonavir, hydroxychloroquine, and interferon β-1b
- PMID: 32544570
- PMCID: PMC7293467
- DOI: 10.1016/j.ijantimicag.2020.106052
Five severe COVID-19 pneumonia patients treated with triple combination therapy with lopinavir/ritonavir, hydroxychloroquine, and interferon β-1b
Keywords: COVID-19; Coronavirus; Hydroxychloroquine; Interferon; Lopinavir/ritonavir; SARS-CoV-2.
Figures
References
-
- WHO Director-General's opening remarks at the media briefing on COVID-19 - 11 March 2020 [https://www.who.int/dg/speeches/detail/who-director-general-s-opening-re...]
-
- Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med. Mar 13 2020 doi: 10.1001/jamainternmed.2020.0994. [Epub ahead of print] - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous
